How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comFluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Description:
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Sponsor:
University of California, San Francisco
Contacts:
Louise Magat (CONTACT)louise.magat@ucsf.edu
(415) 502-1822
Michael Thomas, MD (PRINCIPAL_INVESTIGATOR)Government Study Link:
NCT06474533 - Click here to see study onClinicalTrials.gov
Fluoroethyltyrosine
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Amino Acid Transport
Ligand Class: Small Molecules
Inclusion
- Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
- Recurrent metastatic lesions.
- Recurrent high-grade gliomas (Grades 3 and 4).
- Recurrent low-grade gliomas (Grade 2).
- Presence or suspicion of intracranial neoplasm in two populations:
Exclusion
- Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
Share your feedback
Help us improve your experience